IPOdesktop.com Internet Radio Series Interviews Stanford's Dr. Rod Hentz, Veteran...

IPOdesktop.com Internet Radio Series Interviews Stanford's Dr. Rod Hentz,
Veteran Plastic Surgeon and Physician Consultant to BioSpecifics

LYNBROOK, N.Y., Oct. 14, 2009 (GLOBE NEWSWIRE) -- IPOdesktop.com, in a
continuation of its Internet radio interviews featuring BioSpecifics
Technologies Corp. (Nasdaq:BSTC), today features an interview with Dr. Rod Hentz
of Stanford University School of Medicine, a board-certified plastic surgeon,
and a physician consultant to BioSpecifics. Dr. Hentz has been a participating
consultant in two clinical trials of XIAFLEX. In the interview, Dr. Hentz says
that XIAFLEX is a very effective product, and that he believes its use will be
adopted by plastic and orthopedic surgeons. He anticipates the company's
pioneering XIAFLEX injectable collagenase product will offer these specialists
better non-surgical clinical outcomes.

BioSpecifics is a biopharmaceutical company involved in the development of
injectable collagenase for multiple indications. Dr. Hentz was interviewed by
IPOdesktop.com editor Francis Gaskins. The program can be accessed through the
following link:

http://gaskinsco.com/dr-hentz.mp3

In the interview, Dr. Hentz, who has been a member of the Stanford University
School of Medicine for more than 30 years, notes that he obtained his medical
degree from the University of Florida. Following a residency in general surgery,
he elected to pursue plastic surgery, and became focused on hand surgery,
especially in treating patients suffering from Dupuytren's disease. His mentors
urged pursuing his specialty at Stanford, where a team of a half dozen hand and
upper limb surgeons were based.

For decades, Dr. Hentz says, the standard treatment for relief from Dupuytren's
contracture has been surgical excision of the cords of abnormal tissue that
disfigure the hand. When he became aware of the developments in injectable
collagenase as a surgical alternative, he and his colleagues began to share
thoughts with another medical team at the State University of New York's medical
school at Stony Brook, Long Island.

Dr. Hentz then was asked to participate in two clinical trials of injectable
collagenase -- the first by BioSpecifics in 1999-2000 and more recently by
BioSpecifics' strategic partner, Auxilium Pharmaceuticals.

Presuming FDA approval, Dr. Hentz said, he believes both plastic and orthopedic
surgeons will embrace its use as an alternative to upper hand and limb surgical
procedures.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has
developed injectable collagenase for three clinical indications: Dupuytren's
disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its
strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of
the Biologic License Application (BLA) and Priority Review by the U.S. Food and
Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of
Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM)
product in Europe.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements, other than
statements of historical fact, including statements regarding the company's
strategy, future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management, its expected
revenue growth, and any other statements containing the words "believes",
"expects", "anticipates", "plans", "estimates" and similar expressions, are
forward-looking statements. There are a number of important factors that could
cause its actual results to differ materially from those indicated by such
forward-looking statements, including the ability of its partner Auxilium to
obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's
disease and Peyronie's disease, the preparedness of Auxilium for the commercial
launch of XIAFLEX(TM) for the treatment of Dupuytren's disease and the ability
of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for
these same indications, which will determine the amount of milestone, royalty
and sublicense income payments it may receive; the amount of earn out payments
it may receive from DFB Biotech Inc. and its affiliates; whether Auxilium
exercises its option under the companies' license agreement for additional
indications; the potential benefits of its existing license and development
agreements; its estimates regarding expenses, future revenue, capital
requirements and needs for additional financing; and other factors identified in
the Company's Form 10-K for the year ended December 31, 2008 and the Form 10-Q
for the quarter ended March 31, 2009 and any subsequent reports filed with the
SEC. The Company disclaims any intention or obligation to update any
forward-looking statements as a result of developments occurring after the date
of this press release.

-0-
CONTACT: Investor Relations Network
Tom Gavin
951-845-1112